Latest News for: nsclc

Edit

Cofactor Genomics Advances Predictive Cancer Diagnostics With Landmark OncoPrism-NSCLC Study

Business Wire 18 Dec 2025
... the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC test.
Edit

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC (Nuvectis Pharma Inc)

Public Technologies 17 Dec 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC ... Phase 1b of NXP900 in Combination with Osimertinib in Patients with EGFRmut+ NSCLC.
Edit

ESMO ASIA | HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 11 Dec 2025
HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC ... (NSCLC). About NSCLC.
Edit

ESMO ASIA | HANSOH PHARMA ANNOUNCES MINI ORAL PRESENTATION OF PHASE 1 STUDY OF RISVUTATUG REZETECAN (HS-20093, A B7-H3-TARGETED ADC) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 10 Dec 2025
HANSOH PHARMA ANNOUNCES MINI ORAL PRESENTATION OF PHASE 1 STUDY OF RISVUTATUG REZETECAN (HS-20093, A B7-H3-TARGETED ADC) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) ... NSCLC. ... About NSCLC.
Edit

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

Pharmiweb 09 Dec 2025
“EGFR+ UK is delighted that the Scottish Medicines Consortium has approved amivantamab with chemotherapy for eligible patients in Scotland diagnosed with EGFR Exon 20 insertion mutations NSCLC,” said Prof.
Edit

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented ...

News Graphic 07 Dec 2025
LEXINGTON, Mass., Dec.
Edit

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

PR Newswire 06 Dec 2025
The new analysis evaluated the efficacy and safety of zenocutuzumab-zbco in treatment-naïve and previously treated NRG1+ NSCLC ... NRG1 Gene Fusion Positive Unresectable or Metastatic NSCLC.
Edit

ORIC� Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ...

Nasdaq Globe Newswire 05 Dec 2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases ... .
Edit

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations

Caledonian Record 05 Dec 2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases ....
Edit

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and

Hastings Tribune 03 Dec 2025
Silevertinib delivers robust anti-tumor activity ...
Edit

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans ...

Nasdaq Globe Newswire 03 Dec 2025
BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Edit

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM (Form 8-K) (Black Diamond Therapeutics Inc)

Public Technologies 03 Dec 2025
· PFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinib ... Silevertinib Phase 2 1L NSCLC Initial Clinical Results and Program Update.
Edit

ORIC� Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO ...

Nasdaq Globe Newswire 01 Dec 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET. Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET ... .
Edit

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

PR Newswire 24 Nov 2025
This is the first Phase III clinical trial of ADC combined with immune checkpoint inhibitor to achieve its primary endpoint in the first-line treatment of NSCLC ... metastatic NSCLC with PD-L1 TPS ≥ 1%.
Edit

Final Overall Survival Analysis : HARMONi-A Study Ivonescimab + chemotherapy versus Chemotherapy In patients with EGFR-mutant NSCLC progressed on EGFR TKI (Summit Therapeutics Inc)

Public Technologies 21 Nov 2025
EGFR-mutant NSCLC progressed on EGFR TKI ... EGFR nutations occur in non-snall cell lung cancers (NSCLC) in 15-20% in Whites, and 40-50% in Asians ... The standard first-line therapy for advanced/netastatic EGFR-nutant NSCLC has been EGFR TKIs.

Article Search

tools
×
×
×
×